Loading...
•
Dec 31, 2025
Amicus Therapeutics Q4 2025 Earnings Report
Amicus Therapeutics reported strong fourth quarter 2025 revenue growth with GAAP profitability and continued expansion of Galafold and Pombiliti + Opfolda sales.
Key Takeaways
For Q4 2025, Amicus generated total net product revenue of 185213000, up 24% year over year (20% at constant exchange rates). GAAP net income was 1690000, while non-GAAP net income reached 31630000. Growth was driven by Galafold and Pombiliti + Opfolda demand across global markets.
Fourth quarter total revenue reached 185213000, up 24% year over year.
Galafold revenue was 150239000 in Q4 2025.
Pombiliti + Opfolda revenue was 34974000 in Q4 2025.
GAAP net income was 1690000, with non-GAAP net income of 31630000.
Revenue by Segment
Forward Guidance
Amicus is not providing financial guidance for 2026 due to the pending acquisition by BioMarin expected to close in Q2 2026.
Positive Outlook
- Strong Q4 revenue growth of 24% year over year.
- GAAP profitability achieved in Q4 2025.
- Non-GAAP net income improved year over year.
- Cash position increased to 293536000 at year-end.
- Strong commercial demand across markets.
Challenges Ahead
- Full-year GAAP net loss reported for 2025.
- No 2026 financial guidance provided.
- Pending acquisition creates transaction uncertainty.
- Operating expenses increased year over year.
- Exposure to foreign currency fluctuations.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...